Clinical Trial Update: PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PDR001 in patients with non-small cell lung cancer harboring KRAS/NRAS mutations or no actionable genetic abnormalities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PDR001

Snippet

Sponsor: Asan Medical Center | Conditions: Cancer, Lung Cancer Metastatic | Phase 2 | Status: UNKNOWN